21.4.2024 12:17:53 CEST | Thor Medical ASA | Mandatory notification of trade
primary insiders

Reference is made to the stock exchange announcement made by Nordic Nanovector
ASA (now Thor Medical ASA, the "Company") on 3 July 2023 regarding grant of
restricted share units ("RSU") to the members of the board.

The Company's board of directors has on 19 April 2024 resolved to issue
1,320,469 new shares in the Company towards the current members of the board
pursuant to the RSU-program, of which 486,489 new shares have been issued to
Ludvik Sandes, and 416,990 have been issued to each of John Andersen and Mimi
Kristine Berdal.

Notifications of the transaction in accordance with the Market Abuse Regulation
Article 19 are attached with this announcement.

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.

CONTACTS

 * Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
   brede.ellingseter@thormedical.no 

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visitwww.thormedical.no - https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/3045/4344/Download%20announcement
%20as%20PDF.pdf

Members of BoD Issuance primary insider notification MAR.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/3045/4342/Members%20of%20BoD%20%2
0Issuance%20primary%20insider%20notification%20MAR.pdf